Candriam Luxembourg S.C.A. boosted its stake in TherapeuticsMD Inc (NASDAQ:TXMD) by 45.5% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 480,000 shares of the company’s stock after buying an additional 150,000 shares during the period. Candriam Luxembourg S.C.A.’s holdings in TherapeuticsMD were worth $2,530,000 as of its most recent filing with the SEC.

Other large investors have also recently modified their holdings of the company. Greenwood Capital Associates LLC boosted its stake in shares of TherapeuticsMD by 17.5% in the first quarter. Greenwood Capital Associates LLC now owns 20,309 shares of the company’s stock valued at $146,000 after buying an additional 3,022 shares in the last quarter. Metropolitan Life Insurance Co. NY boosted its stake in shares of TherapeuticsMD by 3.5% in the first quarter. Metropolitan Life Insurance Co. NY now owns 103,048 shares of the company’s stock valued at $742,000 after buying an additional 3,472 shares in the last quarter. American International Group Inc. boosted its stake in shares of TherapeuticsMD by 7.1% in the first quarter. American International Group Inc. now owns 92,415 shares of the company’s stock valued at $665,000 after buying an additional 6,103 shares in the last quarter. Teachers Advisors LLC boosted its stake in shares of TherapeuticsMD by 1.4% in the first quarter. Teachers Advisors LLC now owns 639,602 shares of the company’s stock valued at $4,605,000 after buying an additional 9,077 shares in the last quarter. Finally, Raymond James Financial Services Advisors Inc. boosted its stake in shares of TherapeuticsMD by 56.1% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 28,730 shares of the company’s stock valued at $207,000 after buying an additional 10,330 shares in the last quarter.

TherapeuticsMD Inc (NASDAQ:TXMD) opened at 5.57 on Thursday. The company’s 50-day moving average price is $5.44 and its 200 day moving average price is $5.52. TherapeuticsMD Inc has a 12 month low of $3.50 and a 12 month high of $8.30. The firm’s market capitalization is $1.14 billion.

TherapeuticsMD (NASDAQ:TXMD) last posted its earnings results on Thursday, August 3rd. The company reported ($0.10) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.11) by $0.01. TherapeuticsMD had a negative return on equity of 71.36% and a negative net margin of 530.84%. The business had revenue of $4.25 million for the quarter, compared to analysts’ expectations of $4.91 million. During the same quarter in the previous year, the firm earned ($0.11) earnings per share. The business’s revenue was down 3.4% compared to the same quarter last year. Analysts predict that TherapeuticsMD Inc will post ($0.45) EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Candriam Luxembourg S.C.A. Raises Stake in TherapeuticsMD Inc (NASDAQ:TXMD)” was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The legal version of this news story can be viewed at https://www.dailypolitical.com/2017/08/10/candriam-luxembourg-s-c-a-raises-stake-in-therapeuticsmd-inc-nasdaqtxmd.html.

Several equities research analysts have weighed in on the company. Oppenheimer Holdings, Inc. upgraded TherapeuticsMD from a “market perform” rating to an “outperform” rating and set a $10.00 target price for the company in a report on Tuesday, July 11th. CIBC restated a “market perform” rating and set a $12.00 price objective on shares of TherapeuticsMD in a research note on Tuesday, May 9th. Jefferies Group LLC set a $15.00 price objective on TherapeuticsMD and gave the stock a “buy” rating in a research note on Wednesday, June 14th. Cowen and Company restated an “outperform” rating and set a $13.00 price objective on shares of TherapeuticsMD in a research note on Monday, July 17th. Finally, Deutsche Bank AG began coverage on TherapeuticsMD in a research note on Friday, July 21st. They set a “buy” rating and a $10.00 price objective for the company. One equities research analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $16.14.

About TherapeuticsMD

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Want to see what other hedge funds are holding TXMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TherapeuticsMD Inc (NASDAQ:TXMD).

Institutional Ownership by Quarter for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with MarketBeat.com's FREE daily email newsletter.